Integra LifeSciences

Advances in Wound Care, Nov/Dec 1999 by Thomas, Cathy

Plainsboro, NJ, has received approval for funding of a Phase I grant from the National Institute of General Medical Sciences, through the Small Business Innovation Research (SBIR) fast-track program. A recommendation for funding of a Phase 11 program was also obtained, subject to satisfactory completion of the Phase I program and certain other conditions.

The combined $1.7 million program will support preclinical and clinical development of an RGD-peptide-modifled version of INTEGRA Artificial Skin, which is indicated for treatment of full-thickness bums and other skin wounds. Integra's scientists believe that modifying INTEGRA Artifical Skin with the company's proprietary RGDpeptide technology may accelerate angiogenesis and improve functional and cosmetic outcomes.

In addition, a new device license has been granted for INTEGRA Artificial Skin, which allows the product to be marketed in Canada for use in reconstructive surgery and full-thickness wounds. Indications include scar revision procedures, release of post-bum contractures, congenital skin defects, and revision of hypertrophic and keloid scars.